clinical trial · NCT04601857
Futibatinib and Pembrolizumab Combination in the Treatment of Advanced or Metastatic Urothelial Carcinoma
Taiho Oncology, Inc.·phase2·terminated·n = 43
Advanced and Metastatic Urothelial CancerFutibatinibPembrolizumab
brief summary
The purpose of the trial is to evaluate the antitumor activity and confirm the safety for the combination of Fibroblast Growth Factor Receptor (FGFR) inhibitor futibatinib and anti-programmed cell death-1 (PD-1) antibody pembrolizumab in patients with advanced or metastatic urothelial cancer who are not candidates to receive a platinum-based treatment regimens.
started
Jan 7, 2021
primary completion
Mar 8, 2024
completion
Sep 16, 2025
last updated
Dec 31, 2025
official title
A Phase 2 Study Evaluating Futibatinib (TAS 120) Plus Pembrolizumab in the Treatment of Advanced or Metastatic Urothelial Carcinoma
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol